Search

Your search keyword '"Austad, Joar"' showing total 22 results
Start Over Author "Austad, Joar"
22 results on '"Austad, Joar"'

8. A new scalp formulation of calcipotriene plus betamethasone compared with its active ingredients and the vehicle in the treatment of scalp psoriasis : a randomized, double-blind, controlled trial

Author

Jemec, Gregor B. E., Ganslandt, Cecilia, Ortonne, Jean-Paul, Poulin, Yves, Burden, A. David, de Unamuno, Pablo, Berne, Berit, Figueiredo, Américo, Austad, Joar, Jemec, Gregor B. E., Ganslandt, Cecilia, Ortonne, Jean-Paul, Poulin, Yves, Burden, A. David, de Unamuno, Pablo, Berne, Berit, Figueiredo, Américo, and Austad, Joar

Abstract

BACKGROUND: New topical treatments in scalp psoriasis are needed because many current topical treatments are disliked by patients and associated with poor compliance. OBJECTIVE: To compare the efficacy and safety of once-daily, two-compound scalp formulation containing calcipotriene plus betamethasone dipropionate with the individual components in the same vehicle and the vehicle alone. METHODS: In this 8-week, multicenter, randomized, double-blind study, patients with scalp psoriasis were randomized to treatment with the two-compound scalp formulation (calcipotriene 50 microg/g plus betamethasone 0.5 mg/g, as dipropionate) (n = 541), betamethasone 0.5 mg/g (as dipropionate) in the same vehicle (n = 556), calcipotriene 50 microg/g in the same vehicle (n = 272), or vehicle alone (n = 136). RESULTS: More patients achieved "absent" or "very mild" disease at week 8 with the two-compound scalp formulation (71.2%) compared with betamethasone dipropionate in the same vehicle (64.0%, p = .011), calcipotriene in the same vehicle (36.8%, p < .0001), or the vehicle (22.8%, p < .0001). LIMITATIONS: Efficacy of the active comparators in the study has not been established in relation to calcipotriene and betamethasone formulations available for clinical use. CONCLUSION: Calcipotriene plus betamethasone dipropionate scalp formulation was more effective than either of the individual components or the vehicle alone.

Published
2008
Full Text
View/download PDF

9. Comparative effects of two different calcipotriol (MC 903) cream formulations versus placebo in psoriasis vulgaris. A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Multi-Centre Study

Author

Harrington, Christine I., Goldin, David, Lovell, Christopher R., Van De Kerkhof, Peter, Nieboer, Cees, Austad, Joar, Molin, Lars, Clareus, Birgitta Wilson, Rask-Pedersen, Eva, and Dermatology

Subjects
digestive, oral, and skin physiology, food and beverages, skin and connective tissue diseases
Abstract

Background: Calcipotriol ointment is an effective treatment for psoriasis vulgaris. Although cream formulations have a less emollient effect they are often more acceptable to patients. Objective: To compare calcipotriol 50 μg/g in two different cream formulations with vehicle in patients with psoriasis vulgaris. Method: A randomised, double-blind, parallel group, multi-centre, comparison of cream A in which calcipotriol 50μg/g is dissolved, cream B in which calcipotriol 50 μg/g is suspended as fine particles and vehicle. A 2-week wash-out period was followed by 8 weeks double-blind treatment.

Published
1996
Full Text
View/download PDF

11. Psoriasis of the face and flexures

Author

van de kerkhof, Peter C. M., primary, Murphy, Gillian M., additional, Austad, Joar, additional, Ljungberg, Anders, additional, Cambazard, Frederique, additional, and Bouérat Duvold, Laetitia, additional

Published
2007
Full Text
View/download PDF

14. Phototoxic dermatitis caused by celery infected by Sclerotinia sclerotiorum.

Author

Austad, Joar and Kavli, Gunnar

Subjects
*RADIODERMATITIS, *SCLEROTINIA sclerotiorum, *CELERY, *THIN layer chromatography, *ATOPIC dermatitis, *SPECTROPHOTOMETRY, *PATIENTS
Abstract

11 men developed a severe phototoxic dermatitis of the hands and forearms after harvesting celery infected with Sclerotinio sclerotiorum. By thin-layer chromatography and fluorescence spectrophotometry, xanthotoxin. bergapten and sphondin were isolated. The Canadida albicans test demonstrated xanthotoxin and bergapten as the phototoxic compounds. [ABSTRACT FROM AUTHOR]

Published
1983
Full Text
View/download PDF

15. Effects of PUVA on delayed hypersensitivity in the guinea-pig.

Author

Austad, Joar and Mørk, Nils-Jørgen

Subjects
ULTRAVIOLET radiation, PHYSIOLOGICAL effects of light, DINITROCHLOROBENZENE, PSORALENS, ALLERGIES, ECZEMA, SKIN, GUINEA pigs as laboratory animals
Abstract

Guinea-pigs previously sensitized to dinitrochlorobenzene (DNCB) were topically treated with 8-methoxypsoralen solution and longwave ultraviolet light (PUVA). The animals showed moderate or no clinical and microscopic responses to an elicitation dose of DNCB given immediately after the period of treatment. Exposure to ultraviolet light or psoralen alone did not affect the allergic response. Ten days after PUVA treatment there was a normal eczematous reaction after application of DNCB. [ABSTRACT FROM AUTHOR]

Published
1981
Full Text
View/download PDF

19. Contact dermatitis mimicking photodermatosis in a 1-year-old child.

Author

Helsing, Per and Austad, Joar

Subjects
*CONTACT dermatitis, *SKIN inflammation, *MEDICINE, *SUNSCREENS (Cosmetics), *CHILDREN, *ULTRAVIOLET radiation
Abstract

The article cites a case study related to contact dermatitis mimicking photodermatosis in a one year old child. A one and a half year old child had developed a rash on his trunk after sun exposure. He was administered Nivea milk and Delial to protect him from ultra violet radiation. Sunscreen agents were applied on his face and forearms. Repeated sun exposure over days worsened the exanthema. Examination revealed an erythematous, odematous, slightly scaly eruption on his face and forearms. His condition was assumed to be a light induced dermatitis.

Published
1991
Full Text
View/download PDF

20. Minneord.

Author

Falk, Edvard S., Gjersvik, Petter, and Austad, Joar

Published
2013

21. [Vitamin D, sunbathing and solarium].

Author

Austad J and Lützow-Holm C

Subjects
Humans, Skin metabolism, Sunlight adverse effects, Ultraviolet Rays adverse effects, Vitamin D biosynthesis
Published
2006

22. Psoriasis: severity assessment in clinical practice. Conclusions from workshop discussions and a prospective multicentre survey of psoriasis severity.

Author

van de Kerkhof PC, Kragballe K, Austad J, Berth-Jones J, Cambazard F, de la Brassinne M, Ljungberg A, Murphy G, Papp K, and Wozel G

Subjects
Humans, Prospective Studies, Severity of Illness Index, Surveys and Questionnaires, Psoriasis diagnosis
Abstract

Psoriasis treatment is highly individualized. Although a standardized assessment of psoriasis severity for clinical practice may be theoretically advantageous for the purposes of determining treatment, the relevance of currently available research tools in clinical practice is uncertain. Our objectives were to ascertain in workshop discussions and through a prospective survey the relevance of standard severity measures in clinical practice with regard to choice of treatment. Although there was agreement on the possible structure of an algorithm for the treatment-related definition of psoriasis severity, consensus on the cut-off levels for the PASI and %BSA that would indicate a switch in treatment mode could not be reached. The lack of agreement prompted a prospective survey of 112 patients with psoriasis from 10 countries. This survey used a formal questionnaire asking for the PASI and %BSA scores, the patient's self assessment score (VAS ranging from 0 to 10), location of the psoriatic lesions and disease phase. Severity scores from 20 patients pre-selected for inclusion in a trial of a biological agent were included for comparison. Severity scores were analysed in relation to the choice of treatment (topical or systemic, which included phototherapy and combination) suggested by the treating physician.PASI scores differed significantly between the treatment groups (topical vs systemic, p=0.009); however, there was large overlap in the range of PASI scores between the groups. The same was true for VAS scores (topical vs systemic, p=0.035). %BSA scores were not significantly different between treatment groups. There was a large overlap for both the topical and systemic treatment groups with the biologicals group for the range of both the PASI and %BSA scores. A standardized protocol for the evaluation of psoriasis severity based on established severity scores (PASI, %BSA) appears to be unrealistic in day-to-day clinical practice. In clinical practice, a host of factors must be evaluated alongside possible metric measures. This requires experience and the specialized medical education of those involved in the treatment of patients with psoriasis.

Published
2006

Catalog

Books, media, physical & digital resources
See catalog results